Allogeneic HSCT is a curative treatment for high-risk leukemia. In Europe, approximately 15% of children have an HLA-matched sibling, but in 65-70% HLA allelematched (9-10/10) unrelated donors (UD) can be identified. Transplantation using an HLA partially mismatched donor, unrelated cord blood or haploidentical family donor with graft manipulation is then considered with preference on the basis of local experience and/or availability. Here we evaluate the outcomes of 87 consecutive patients with leukemia transplanted with unmanipulated graft from matched or partially mismatched UD or cord blood (CB) at our institution between January 2001 and December 2007. Within the median follow-up of 30 months, the acute GVHD grade II was diagnosed in 70.9% patients; grades III-IV only in 4.6%. The overall incidence of chronic GVHD was 43.3% (extensive in 34.9%). The probability of 3-year EFS was 59.5% and that of 3-year overall survival was 66.9%. TRM at day þ 100 was 4.5%, and overall it was 13.8%. Fourteen patients (16.1%) died as a consequence of post-transplant leukemia relapse. We conclude that the prognosis of patients transplanted for leukemia using unmanipulated grafts from HLA-matched or partially mismatched UD or CB is comparable and satisfactory. TRM and relapse rate are lower than in the earlier period.
Introduction
Allogeneic HSCT is a potentially curative treatment for advanced stage leukemia. It is often indicated in patients with leukemia where response to chemotherapy is inadequate (ALL, AML) or the disease affects the population of hematopoietic stem cells (myelodysplastic syndrome (MDS), CML). In approximately 15% of children eligible for HSCT, HLA-matched sibling donor could be available. For the rest, a search for alternative donor needs to be initiated. In approximately 65-70% of children without matched sibling donor, HLA allele-matched (9-10/10; A*, B*, Cw*, DRB1*, DQB1*) unrelated donors (UD) can be identified. The selection of UD according to HLA allele match led to improvement of survival. However, strict observance of HLA matching (9-10/10) decreases the pool of potential donors for those for whom such matched UD could not be identified. In our experience, for approximately 15-20% of patients we are not able to find a socalled 'well-matched' (9-10/10 HLA allele match) related or UD. In this cohort, the infusion of a graft from an HLApartially mismatched donor (7-8/10), unrelated cord blood (UCB; 4-5/6) or haploidentical family donor with graft manipulation is then considered with preference being based mostly on local experience and/or availability. 1, 2 However, all these alternatives have an increased risk of post-transplant morbidity/mortality, especially because of an increased risk of GVHD and slow immune reconstitution. 2, 3 Furthermore, in patients with malignancies, manipulation of the graft may adversely affect a favorable alloreactive effect directed against the residual disease. 4 
Aims, patients/materials, methods
We evaluated the outcomes of 87 consecutive patients with high-risk or advanced stage leukemia transplanted with unmanipulated graft from an HLA-matched or mismatched UD or UCB at our institution between January 2001 and December 2007. The aim was to compare the outcomes of those who underwent HSCT using PBSC, BM or cord blood (CB) of well-matched or partially mismatched UD. A written informed consent was obtained from patients or their legal guardians. [5] [6] [7] HLA typing using PCR methods was routinely available at our institution since the beginning of 1999. HLA genotyping of loci HLA-A*, -B*, -Cw*, -DRB1* and -DQB1* by PCR-SSP with GenoVision kits, and by SBT with ABBOTT kits was prospectively performed in all patient/donor pairs. Patients (1.0-20.5; median 12.2 years) were transplanted for ALL 39 (CR1: 11 Â , CR2: 21 Â , CR3: 5 Â , PR2 þ 3: 2 Â ; Ph þ : 14 Â ), AML 12 (CR2: 10 Â , CR3: 2 Â ), AHL 2, secondary AL/MDS 8, MDS 15 (JMML: 3 Â ), CML 9 (1st chronic phase (CP1): 7 Â , AP/ BC: 2 Â ), NHL 1 (CR3: 1 Â ) and idiopathic myelofibrosis 1.
For HSCT using adult donors single allele mismatch at A*, B* or DRB1* in GVHD direction (5-6/6) was acceptable with preference to have the best available match at Cw* and DQB1*; for UCB, 4-5/6 match was acceptable (A and B low-, DRB1 high-resolution) with the preference of units with large cell doses. Owing to lower cell doses double cords were used in two patients from our cohort. DPB1* alleles were retrospectively typed in all 27 patient/donor pairs fully matched in 10/10 HLA alleles. Only three of them (11%) were confirmed as full-matched pairs in 12/12. Two of those patients received PBSC and one was transplanted with BM. All these three patients also received serotherapy. All developed grade II acute GVHD (aGVHD) and two of them also developed extensive chronic GVHD (cGVHD). One of them died because of post-transplant relapse (high minimal residual disease pretransplant, ALL Ph þ in CR1) and two are alive in continuous post-transplant remission. Now, both are off immunosuppressive therapy.
As a primary graft, BM was used in 35 (40%), PBSC in 42 (48%) and CB in 10 (11.5%, double cord 2 Â ) patients (Table 1) . GVHD prophylaxis consisted of CsA (n ¼ 86), MTX (n ¼ 75), steroids (n ¼ 8), mycophenolate mofetil (n ¼ 3), rabbit antithymocyte globulin (Fresenius; n ¼ 80; 40 mg/kg total in 76), campath 1H (n ¼ 1), thymoglobuline (n ¼ 1) and no serotherapy in five patients. The prophylactic CsA started at day-1 before infusion of the graft, was given in 2-3 daily infusions (over 2 h) to maintain the trough serum levels of 150-250 ug/l (method of detection-FPIA). MTX was given on days þ 1, þ 3 and þ 6. The first dose was 10 or 15 mg/m 2 (higher dose in the earlier period) and other doses were 10 mg/m 2 . Leucovorin (15 mg/m 2 ) was given as a single dose 24 h after each MTX dose. MTX was not used in any of the patients transplanted with CB. The conditioning regimen varied according to the disease but was myeloablative in 97% of patients. TBI was used in 48 patients (55%; 12 Gy in 37; 14.4 Gy in 11 patients). BU (16 mg/kg) was used in 36 patients (41%), and 3 patients were conditioned with other conditioning regimen. Only 56 patients (64%) were transplanted using HLA 9-10/10 allele-matched UD, 21 from 7-8/10 matched UD, 10 from 4-5/6 (A, B low-resolution; DRB1 high-resolution) matched UCB. The day of neutrophil engraftment was defined as the first of 3 consecutive days when the ANC reached 0.5 Â 10 9 /l or more. Platelet engraftment was Table 1 Characteristics of primary grafts and engraftment defined as platelet count 20 Â 10 9 /l or more for 7 consecutive days without transfusion. Chimerism was assessed by using PCR-based analyses of polymorphic variable number tandem repeats or short tandem repeats on recipients from unseparated peripheral blood, frequently starting on day þ 14 and then once weekly until day þ 100, later less frequently in patients with stable full donor chimerism, to confirm efficient engraftment and to rule out the risk of late graft failure/rejection or relapse.
EFS is calculated from the date of transplantation to the last follow-up or first event (death or relapse of the primary disease, whichever occurred first). The Probabilities of EFS and overall survival (OS) are estimated using the KaplanMeier method and all analyses were calculated using Statview software (SAS Institute, version 5).
Results

Hematopoietic engraftment and chimerism
Full trilineage stable primary engraftment was achieved in 86 children (99%), with one patient who died too early (at day þ 1) from severe multiorgan failure. Engraftment characteristics are listed in Table 1 . Complete donor chimerism before day þ 100 was observed in 85 of 86 (99%) evaluable patients and could be documented after a median of 21 days (range 14-98).
GVHD incidence and severity Acute GVHD grade II was diagnosed in 61 (70.9%) patients; grade III-IV in 4 (4.6%). Overall incidence of cGVHD in 83 evaluable patients at any time post transplant was 43.3%; 8.4% experienced limited and 34.9% extensive, respectively (Table 2) . ). However, in only one patient (AML) was donor lymphocyte infusions efficient to establish durable response. In most patients, it only postponed the progression to full hematological relapse. Leukemia relapse occurred in 20 (ALL 13 Â , AML 5 Â , CML 1 Â , MDS 1 Â ) out of 86 evaluable patients (23.2%) 105-842 days after HSCT (median 369 days). Seven of these 20 patients (35%) subsequently underwent chemotherapy, achieved CR and were retransplanted from the same donor (n ¼ 6) or other UD (n ¼ 1, after primary CB transplant) 336-738 days (median 479) following first HSCT. One of them subsequently died because of further relapse (ALL; day þ 275), one is alive in relapse with no response to additional donor lymphocyte infusions (AML; þ 13 months) and one died from toxicity following second HSCT (ALL; day þ 45). Four (57%; MDS, ALL, AML, AML) are alive in molecular-genetic remission (7, 37, 38 and 56 months) after second HSCT. The last one was treated for isolated testicular relapse with chemotherapy, surgery and local radiation and is alive in further remission now 875 days after the diagnosis of testicular relapse.
Overall outcome TRM at day þ 100 was 4.5% with overall TRM being 13.8% (Table 2) . Altogether, 12 patients died as a consequence of transplantation at a median of 213 days post transplant (range 1-602). Five patients were affected with viral infection (CMV 3 Â , ADV 1 Â , BKV 1 Â), six patients with invasive fungal infection (Aspergillus 3 Â , Zygomycetes 1 Â, Candida non-albicans 2 Â ) and seven patients died because of extensive cGVHD. Median follow-up till first event or last follow-up of total cohort is 1.8 years (range 0-6.9 years). EFS of total cohort was 59.5% (95% CI 48.5-70.5), and 3-year OS was 66.9% (95% CI 56.3-77.5) (Figure 1 ).
According to the type of graft, median follow-up is 2.06 for PBSC (range 0.13-6.9 years), 2.3 for BM (range 0.003-6.95 years) and only 0.96 (range 0.29-4.8) for the CB group. There is no difference in EFS between patients transfused with BM or PBSC, respectively ( Figure 2 ). The probability of 3-year EFS of the BM group was 57.9 (95% CI 41-74.8) and that of 3-year OS was 67% (95% CI 50.9-83). The 3-year EFS of the PBSC group was 63.7 (95% CI 48. and that of OS was 71.6% (95% CI 57.2-85.9). The 1-year EFS of the CB group was 47% (95% CI 9.9-84.6) and that of 1-year OS was 62% (95% CI 27.4-97.1). The 1-year EFS of CB group was calculated because of the low median follow-up of this group. The probability of 3-year survival of patients following HSCT from HLA allele partially mismatched (7-8/10) donors is as follows: n ¼ 21; EFS 70.5%, CI 50.5-90.4 and OS 75% CI 55.9-94. The 3-year survival of patients following HSCT from HLA allele-matched (9-10/10) donors is as follows: n ¼ 56; EFS 57%, CI 43.3-70.8 and OS 67.1%, CI 54.1-80. The difference in survival according to HLA match 7-8/10 versus 9-10/10 is not statistically significant (Cox-Mantel test) (Figure 3) .
Discussion or future perspectives
Consideration of potential donors for transplantation includes a rigorous assessment of the availability and HLA-match status of family members, and the identification of suitable UD when related donors are not available. Because HLA gene products provoke host-versus-graft and graft-versus-host alloimmune responses, HLA matching serves a critical preventive role in lowering risks of graft failure and GVHD. At the same time, GVL effects associated with HLA mismatching may provide an immunological means of lowering the recurrence of posttransplant disease in high-risk patients. The definition of a suitable allogeneic donor is ever changing, shaped not only by current typing technology for the known HLA genes but also by the specific transplant procedure. The increased safety of alternative donor hematopoietic cell transplantation has been achieved in part through advances in the field of immunogenetics. The increased availability of HSCT through the use of HLA-mismatched related and UD is feasible with a more complete understanding of permissible HLA mismatches and the role of NK-KIR genes in transplantation. 8 An increasing number of centers worldwide successfully use UCB 9 where the naive immune system permits reduced stringency of HLA, and therefore within the acceptable level of mismatch it is possible to find a suitable donor for the majority of children. Its wide use, though, is limited by the efficient cell dose available for older children and adults. 10, 11 This can be overcome by using double CB transplants. 12 Other disadvantages include naivete of immunity against viruses and unavailability of CB for potential adoptive immunotherapy or retransplantation.
Recently, patients with CML in CP1 are no longer considered as a high-risk population. For such patients, frontline therapy with imatinib is available. The indication for SCT is considered locally based mostly on the availability of matched donor. Transplantation using fully matched donors in patients with very good response to imatinib enables the use of reduced-intensity conditioning. We should state that out of seven patients with CML in CP1 transplanted in our cohort following myeloablative conditioning with TBI, all are alive and well in molecular remission, without any need for post-transplant donor lymphocyte infusions, and currently all are without any signs of cGVHD. All remain off any immunosuppressive therapy.
We present our experience with transplantations using HLA-matched or mismatched UD without any in vitro graft manipulation. The majority of patients received serotherapy pretransplant. Only five patients (5.7%) with high levels of minimal residual disease and HLA wellmatched donor received no serotherapy. HLA-mismatched UD were prospectively selected on the basis of the level of allele match. We and others speculate that allele or antigen mismatch is equally adverse to survival. In our clinical experience, UD with up to 3 allele mismatches out of 10 tested (not more than one in loci A*, B* or DRB1*) could be used for a patient with malignant disease with acceptable risk for toxicity if adequate serotherapy is given together with a myeloablative conditioning regimen. In contrast, we speculate that the practice still used in many centers to select donors based on HLA match in A*, B* or DRB1* loci, with no respect to numbers of potential mismatches in Cw* and/or DQB1* loci, is not efficient. This approach may explain the inferior outcome results compared with those achieved in our cohort. It is not rare to have many Cw* and/or DQB1* mismatches even in donor/recipient pairs otherwise allele matched in 5-6/6 in standard A*, B* and DRB1* loci. There is a consensus that the matching of UD and patients for HLA class II alleles improves the outcome of HSCT. However, the significance of HLA class I allelic mismatches for transplant outcome is under ongoing discussion and reports on long-term effects such as cGVHD are rare.
On the basis of our results and together with information published so far, 13 we also conclude that the high resolution of HLA alleles, both class I and class II, have an important function in the selection of a suitable UD. However, when a fully matched donor is not available, we show that GVHD prophylaxis with rabbit antithymocyte globulin enables the use of an unmanipulated graft from partially mismatched donor without excessive risk of poor outcome owing to severe aGVHD and/or extensive cGVHD. The incidence of severe aGVHD (grades III-IV) in our cohort is low and therefore its influence on TRM is minor. The high incidence of extensive cGVHD in our cohort (34.9%) may explain the lower relapse rate in such high-risk cohort. Although cGVHD may be devastating, it was not so in a majority of our patients. Our limited experience shows that in younger children, cGVHD diminishes within a relatively short period. Many patients were free of symptoms when they were on immunosuppressive therapy. We have observed more severe cGVHD in adolescents. Extensive cGVHD was frequently associated with previous adoptive therapy for emerging relapse and/or adolescents with MDS irrespective of the level of HLA match. Out of 18 patients with extensive cGVHD transplanted 24 months or more ago, 3 died (TRM), 6 are still on immunosuppressive therapy free of symptoms and 9 (50%) are off any therapy since less than 24 months after SCT.
Conclusions
For patients without a fully matched UD, even HSCT of unmanipulated graft from partially mismatched donor or CB might be a feasible alternative. Owing to high heterogeneity of our cohort, it is difficult to speculate about different GVL effects according to HLA match or type of graft. Especially in patients with ALL, the risk of relapse was strongly correlated with the level of minimal residual disease in BM immediately before SCT. 14 In our cohort, the TRM remains low irrespective of the HLA match of the donor and/or used type of graft. The high incidence of both aGVHD and cGVHD might also explain the relatively low relapse rate in such cohort. Good control of leukemia pre-transplant, however, remains to have a crucial function in preventing leukemia relapse posttransplant. In the future, we would like to guide the timing of HSCT, more according to the level of residual leukemia within the use of targeted therapy and/or monoclonal antibodies and/or additional blocks of chemotherapy with the use of new chemotherapeutic drugs.
Transplantation using any HLA-mismatched alternative donor is a risky procedure and demands a high level of care during and especially after transplantation.
